EU approves AstraZeneca’s Calquence in combo with venetoclax, with or without obinutuzumab to treat adult patients with previously untreated CLL: Cambridge, UK Saturday, June 7, ...

A fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) in combination with venetoclax, with or without ...

AstraZeneca (AZ) has announced that its fixed-duration Calquence (acalabrutinib)-based regimens have been approved by the ...

Drugmaker AstraZeneca said on Friday that it had received approval from the European Commission for fixed-duration regimens ...

AstraZeneca (LSE: AZN) has received European approval for a fixed-duration regimen of Calquence (acalabrutinib) in ...

"Calquence plus venetoclax is the first and only all-oral combination treatment option with a second-generation BTK inhibitor ...

(RTTNews) - AstraZeneca said a fixed-duration regimen of Calquence in combination with venetoclax, with or without obinutuzumab, has been approved in the European Union for the treatment of adult ...

AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.

OPEN The FTSE 100 was expected to open 6.2 points lower on Friday after closing 0.11% higher in the previous session at 8,811.04.

AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...